OrganonOGN +0.22%73 Pretax Margin % is 14.59% as of Mar. 2026, which is 31% below its 10-year median of 21.21. GuruFocus rates OGN with a GF Score™ of 73/100 and a GF Value™ of $14.55 (Fairly Valued). The stock has 9 warning signs investors should review. Among 955 Drug Manufacturers companies, Organon ranks better than 54.45% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Organon's Pre-Tax Income for the
three
months ended in Mar. 2026 was $213 Mil. Organon's Revenue for the
three
months ended in Mar. 2026 was $1,460 Mil. Therefore, Organon's pretax margin for the quarter that ended in Mar. 2026 was 14.59%.
The historical rank and industry rank for Organon's Pretax Margin % or its related term are showing as below:
OGN'
s Pretax Margin % Range Over the Past 10 Years
Min: 6.84 Med: 21.21 Max: 47.52
Current: 8.71
OGN's Pretax Margin % is ranked better than 54.45% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs OGN: 8.71
Organon (NYSE:OGN) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Organon Pretax Margin % Related Terms
Organon Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Organon's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OGN vs AMRN, SCLX, MIRA: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Organon's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Organon's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organon (OGN) has a Pretax Margin % of 14.59% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Organon and its competitors. This is 31% below median its historical median of 21.21. Over the past decade, Organon's Pretax Margin % has ranged from 6.84 to 47.52. According to the industry distribution chart, Organon ranks #435 out of 955 companies in the Drug Manufacturers industry, placing it in the top 45.5%.
Is Organon's Pretax Margin % too high?
Organon's current Pretax Margin % of 14.59% is 31% below median its 10-year median of 21.21. Over the past 10 years, this metric has ranged from a low of 6.84 to a high of 47.52. The Drug Manufacturers industry median Pretax Margin % is 7.28. Organon's value of 14.59% is 100.4% above this industry median. Based on the distribution chart, Organon ranks #435 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Organon has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Pretax Margin % compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #435 out of 955 companies for Pretax Margin %. This puts Organon in the upper half of its industry. The industry median Pretax Margin % is 7.28. Organon's value of 14.59% is 100.4% above this benchmark. Historically, Organon's own Pretax Margin % has ranged from 6.84 to 47.52 over the past decade. While the company's 10-year median is 21.21 vs. the industry median of 7.28, Organon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organon's current Pretax Margin % of 14.59% is 100.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Organon and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organon's current Pretax Margin % is 14.59%, which is 31% below median its own 10-year median of 21.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.55, compared to a current price of $13.48 — trading 7.4% below its estimated fair value. The current Pretax Margin % is 14.59%, which is 31% below median its 10-year median of 21.21 and 100.4% above the Drug Manufacturers industry median of 7.28. Organon's overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Organon (OGN), the current Pretax Margin % is 14.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of $13.48 is trading 7.4% below its estimated GF Value™ of $14.55.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
Pretax Margin %: 14.59% (31% below median its 10-year median of 21.21)
GF Value™: $14.55 vs. price of $13.48 (7.4% below fair value)
Industry Position: 100.4% above the Drug Manufacturers median (#435 of 955)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
73GF Score
Get the complete analysis for OGN
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
